Adjuvant dabrafenib plus trametinib versus placebo in patients with resected, BRAFV600-mutant, stage III melanoma (COMBI-AD): exploratory biomarker analyses from a randomised, phase 3 trial-Reference-Cited by-同舟云学术

Adjuvant dabrafenib plus trametinib versus placebo in patients with resected, BRAFV600-mutant, stage III melanoma (COMBI-AD): exploratory biomarker analyses from a randomised, phase 3 trial

Published:2020-03 Issue:3 Volume:21 Page:358-372
ISSN:1470-2045
Container-title:The Lancet Oncology
language:en
Short-container-title:The Lancet Oncology

Author:

Dummer Reinhard,Brase Jan C,Garrett James,Campbell Catarina D,Gasal Eduard,Squires Matthew,Gusenleitner Daniel,Santinami Mario,Atkinson Victoria,Mandalà Mario,Chiarion-Sileni Vanna,Flaherty Keith,Larkin James,Robert Caroline,Kefford Richard,Kirkwood John M,Hauschild Axel,Schadendorf Dirk,Long Georgina V

Publisher

Elsevier BV

Subject

Oncology

Reference30 articles.

1. Adjuvant dabrafenib plus trametinib in stage III BRAF-mutated melanoma;Long;N Engl J Med,2017

2. Longer follow-up confirms relapse-free survival benefit with adjuvant dabrafenib plus trametinib in patients with resected BRAF V600-mutant stage III melanoma;Hauschild;J Clin Oncol,2018

3. Adjuvant pembrolizumab versus placebo in resected stage III melanoma;Eggermont;N Engl J Med,2018

4. Adjuvant therapy with nivolumab (NIVO) versus ipilimumab (IPI) after complete resection of stage III/IV melanoma: updated results from a phase III trial (CheckMate 238);Weber;Proc Am Soc Clin Oncol,2018

5. The new era of adjuvant therapies for melanoma;Eggermont;Nat Rev Clin Oncol,2018

Cited by 90 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Dabrafenib and trametinib administration in patients with BRAF V600E/R or non-V600 BRAF mutated advanced solid tumours (BELIEVE, NCCH1901): a multicentre, open-label, and single-arm phase II trial;eClinicalMedicine;2024-03

2. Neoadjuvante Therapie des Melanoms;best practice onkologie;2024-01-05

3. Current surgical management for melanoma;The Journal of Dermatology;2023-12-27

4. The impact of genomic context on outcomes of solid cancer patients treated with genotype-matched targeted therapies: a comprehensive review;Annals of Oncology;2023-12

5. Characteristics of Real-World Patients with High-Risk BRAFV600E/K-Mutated Melanoma Receiving Adjuvant Treatment with Dabrafenib Plus Trametinib After Surgical Resection, Through the Italian Managed Access Program;Cancer Management and Research;2023-11